Community Oncology Surveyed Bispecific Therapy Access

Independent practices reported significant barriers to providing complex cancer treatments in office settings.

Updated on Sept. 22, 2026 in Cancer

Isometric editorial illustration of a glass medical vial and a stainless steel tray, representing clinical oncology infrastructure.
A new survey from the Community Oncology Alliance reveals that independent clinics face substantial financial and logistical hurdles in administering complex bispecific cancer therapies. AI Illustration. Upload story photo >

Live Poll

Should medical practices receive higher reimbursement for performing intensive patient monitoring tasks?

The Community Oncology Alliance surveyed 104 independent oncology practices in June and July 2026 to assess the delivery of bispecific therapies. Findings released on September 22, 2026, highlighted logistical and financial hurdles hindering broader administration.

Why it matters

The survey underscores persistent infrastructure gaps for independent clinics, which are critical for increasing patient access to advanced cancer care. Addressing these operational challenges is essential to ensure that novel therapies reach patients outside of large hospital systems.

A survey of 104 practices found that 91.4 percent administer bispecific therapy in-office, while 32.9 percent of clinics operate more than 25 miles from a hospital capable of managing therapy-related side effects.

The players

Community Oncology Alliance

This is a non-profit organization dedicated to advocating for community oncology practices and the patients they serve.

The details

Independent practices across the country identified difficult coordination with hospitals for managing complex side effects like CRS and ICANS as a top obstacle. Additionally, over a third of respondents cited a lack of reimbursement for the staff time required to monitor patients during these specialized treatments.

Timeline

  1. The survey fielding period ran from June 2026 through July 2026.

  2. The Community Oncology Alliance announced the results on September 22, 2026.

The Big Picture

This study updates the data foundational to the Community Oncology Alliance's advocacy framework, which is currently focused on addressing the unique reimbursement and logistical needs required for the delivery of modern, complex cancer therapies.

Patients may face limited options for receiving bispecific therapies if their local independent clinic lacks the infrastructure or reimbursement support to provide these treatments. These findings highlight a critical need for policy changes to ensure that specialized cancer care remains accessible within local communities.

The takeaway

The survey highlights that while most independent clinics are willing to administer complex therapies, the current reimbursement model does not adequately support the high intensity of staff monitoring required. Expanding access will require updated clinical monitoring tools and standardized billing codes to offset these operational costs.

Further reading

For more information on the current landscape of cancer care, visit the Cancer section.

More information

Review the full COA bispecific survey results on the Community Oncology Alliance website.

Source note: This article includes information reported by Firstwordpharma.

Live Poll

Should medical practices receive higher reimbursement for performing intensive patient monitoring tasks?